Sai Life Sciences, founded in 1999 in Hyderabad, is a fully integrated contract research, development, and manufacturing organisation that provides end-to-end scientific solutions — from early discovery through commercial manufacturing for small and large molecules. In December 2024, the company listed on Indian stock exchanges, marking a quarter-century journey from a startup laboratory to a publicly traded global CRDMO.
Most pharmaceutical services companies do one thing: they either discover molecules, or develop processes, or manufacture at scale. Sai Life Sciences set out to do all three. The company was founded in 1999 with a premise that was ambitious for a Hyderabad startup — build a single organisation that could take a client’s molecule from the earliest stages of discovery chemistry through process development, clinical-scale production, and ultimately commercial manufacturing.
The pharmaceutical industry has a name for this model: CRDMO, for contract research, development, and manufacturing organisation. The acronym is clunky, but the idea is powerful. When a biotech company identifies a promising compound, it typically works with a chain of specialised vendors — one for medicinal chemistry, another for process optimisation, a third for formulation, a fourth for commercial production. Each handoff introduces risk: knowledge lost in translation, timelines extended, quality standards misaligned.
Sai’s integrated model eliminates the handoffs. A molecule that enters Sai’s discovery labs can move through every subsequent stage within the same organisation, with the same scientific teams tracking it from gram-scale synthesis to tonne-scale production. For the innovator companies that are Sai’s clients, this continuity translates directly into speed and predictability — two things the pharmaceutical development process is famously short on.
What distinguishes Sai from many Indian pharmaceutical services companies is the way it has structured its global operations. Discovery and development laboratories, along with manufacturing facilities, are located in India — where the depth of scientific talent and the economics of operation provide a structural advantage. Client-facing teams, however, are embedded in the United States and Europe, where the innovator pharmaceutical and biotech companies that Sai serves are headquartered.
This is not offshoring in the traditional sense. It is a delivery model designed so that the scientists who manage client relationships understand the regulatory environment, development timelines, and commercial pressures of the US and European markets, while the laboratories doing the work operate in an ecosystem where a thousand-person chemistry team is buildable and sustainable. The model requires investment in both directions: Sai has built significant infrastructure in Hyderabad while simultaneously growing its presence in Boston, San Francisco, and across Europe.
The result is a company that thinks globally but executes in India — the kind of organisation that global pharma and biotech firms increasingly seek as they look for partners who can deliver quality science at a pace and cost structure that in-house operations struggle to match.
In December 2024, Sai Life Sciences listed on the BSE and NSE — Indian stock exchanges that together constitute one of the world’s largest equity markets. The IPO was a milestone not just for the company but for the Indian CRDMO sector, which has grown from a niche within pharmaceutical services to a recognised category attracting significant institutional capital.
For Sai, the listing marked the end of twenty-five years as a private company and the beginning of a phase where growth ambitions are backed by public market resources. The company’s FY25 revenue of $203 million, up from $177 million the prior year, suggests that the transition to public ownership has not disrupted the commercial momentum. With 3,401 employees and capabilities spanning both small molecules and large molecules, Sai enters the public markets as one of a small number of Indian CRDMOs with genuinely end-to-end capability.
The timing was deliberate. The global pharmaceutical industry is in the midst of a structural shift toward outsourced development and manufacturing, driven by the proliferation of biotech companies that have scientific ideas and clinical programmes but not the infrastructure to make medicines at scale. Sai’s listing positions it to compete for this expanding pool of work with the capital to invest in capacity, capabilities, and geographic reach.
Sources: Sai Life Sciences Annual Reports FY2024–FY2025. US FDA facility registration data.